Literature DB >> 6722018

Deaths occurring in newly notified patients with pulmonary tuberculosis in England and Wales.

M J Humphries, S P Byfield, J H Darbyshire, P D Davies, A J Nunn, K M Citron, W Fox.   

Abstract

In a survey of the chemotherapy prescribed for 1312 adult patients of white or Indian subcontinent ethnic origin with pulmonary tuberculosis only, notified in the 6 months from October 1978 to March 1979, it was found that 163 (12%) patients died before they had completed chemotherapy. Of the 163 patients who died 96% were of white ethnic origin; 15% of the 1022 white patients died compared with 2% of the 290 Indian subcontinent patients. According to the death certificate, approximately half the white patients died from tuberculosis, and in a further 31% tuberculosis was a contributory factor. Death from tuberculosis most frequently occurred in the older age groups, accounting in part for the different findings in these two ethnic groups, because of the excess of older white patients. In a step-wise multivariate discriminant analysis death from tuberculosis was found to be significantly associated in the white patients with the radiographic extent of disease before treatment, and with age, extent of cavitation and a positive sputum smear result, but not sex. Most of the deaths from tuberculosis occurred early, 38% before the end of the first week of chemotherapy and 69% by the end of 4 weeks. There was a further group of 51 adult patients with pulmonary tuberculosis notified in the same 6-month period in whom the diagnosis was not made until after death, 25 of them dying from tuberculosis. It is concluded that there is still a substantial risk of death from tuberculosis in patients with extensive disease in the older age groups.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6722018

Source DB:  PubMed          Journal:  Br J Dis Chest        ISSN: 0007-0971


  21 in total

1.  Current trends in tuberculosis mortality in England and Wales.

Authors:  M Nisar; P D Davies
Journal:  Thorax       Date:  1991-06       Impact factor: 9.139

2.  Hepatotoxicity of antituberculosis drugs.

Authors:  L P Ormerod; C Skinner; J Wales
Journal:  Thorax       Date:  1996-02       Impact factor: 9.139

Review 3.  Ethnic differences in respiratory diseases.

Authors:  D Honeybourne
Journal:  Postgrad Med J       Date:  1987-11       Impact factor: 2.401

4.  Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas.

Authors:  J-Y Wang; P-R Hsueh; I-S Jan; L-N Lee; Y-S Liaw; P-C Yang; K-T Luh
Journal:  Thorax       Date:  2006-06-29       Impact factor: 9.139

5.  Clinical value of the measurement of Mycobacterium tuberculosis specific antibody in pulmonary tuberculosis.

Authors:  G H Bothamley; R Rudd; F Festenstein; J Ivanyi
Journal:  Thorax       Date:  1992-04       Impact factor: 9.139

6.  Proceedings of the British Thoracic Society. 1988 summer meeting. 13-15 July, Newcastle upon Tyne. Abstracts.

Authors: 
Journal:  Thorax       Date:  1988-10       Impact factor: 9.139

7.  Treatment of pulmonary tuberculosis in patients notified in England and Wales in 1978-9: chemotherapy and hospital admission. Medical Research Council Tuberculosis and Chest Diseases Unit.

Authors: 
Journal:  Thorax       Date:  1985-02       Impact factor: 9.139

8.  Tuberculosis treatment outcome monitoring in England, Wales and Northern Ireland for cases reported in 2001.

Authors:  Delphine Antoine; Clare E French; Jane Jones; John M Watson
Journal:  J Epidemiol Community Health       Date:  2007-04       Impact factor: 3.710

9.  Global tuberculosis incidence and mortality during 1990-2000.

Authors:  P J Dolin; M C Raviglione; A Kochi
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

Review 10.  Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis.

Authors:  Dick Menzies; Andrea Benedetti; Anita Paydar; Ian Martin; Sarah Royce; Madhukar Pai; Andrew Vernon; Christian Lienhardt; William Burman
Journal:  PLoS Med       Date:  2009-09-15       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.